Martina Mcdermott • UCLA Profiles (original) (raw)

  1. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers. Mol Cancer Ther. 2023 12 01; 22(12):1365-1375. O'Brien NA, McDermott MSJ, Zhang J, Gong KW, Lu M, Hoffstrom B, Luo T, Ayala R, Chau K, Liang M, Madrid AM, Donahue TR, Glaspy JA, Presta L, Slamon DJ. PMID: 37788341.
    View in: PubMed Mentions: 10 Fields:
    Translation:HumansAnimalsCells
  2. Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Mol Cancer. 2023 Oct 30; 22(1):175. McDermott MSJ, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. PMID: 37915024; PMCID: PMC10614316.
    View in: PubMed Mentions: Fields:
  3. Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy. Br J Cancer. 2023 10; 129(6):1022-1031. Gaynor N, Blanco A, Madden SF, Moran B, Fletcher JM, Kaukonen D, Ramírez JS, Eustace AJ, McDermott MSJ, Canonici A, Toomey S, Teiserskiene A, Hennessy BT, O'Donovan N, Crown J, Collins DM. PMID: 37507543; PMCID: PMC10491671.
    View in: PubMed Mentions: 8 Fields:
    Translation:HumansCellsCTClinical Trials
  4. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors. Clin Cancer Res. 2023 06 01; 29(11):2131-2143. McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong JJ, Chau K, Davenport S, Xie B, Press MF, Panayiotou R, Handly-Santana A, Brugge JS, Presta L, Glaspy J, Slamon DJ. PMID: 36884217; PMCID: PMC10233360.
  5. Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo. Proc Natl Acad Sci U S A. 2022 08 09; 119(32):e2201073119. Ding X, Sharko AC, McDermott MSJ, Schools GP, Chumanevich A, Ji H, Li J, Zhang L, Mack ZT, Sikirzhytski V, Shtutman M, Ivers L, O'Donovan N, Crown J, Gyorffy B, Chen M, Roninson IB, Broude EV. PMID: 35914167; PMCID: PMC9371674.
    View in: PubMed Mentions: 20 Fields:
    Translation:HumansAnimalsCells
  6. Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies. Mol Cancer Ther. 2022 05 04; 21(5):751-761. O'Brien NA, Huang HKT, McDermott MSJ, Madrid AM, Luo T, Ayala R, Issakhanian S, Gong KW, Lu M, Zhang J, Slamon DJ. PMID: 35417017.
    View in: PubMed Mentions: 17 Fields:
    Translation:Humans
  7. The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs. Cells. 2021 01 12; 10(1). Sharko AC, Lim CU, McDermott MSJ, Hennes C, Philavong KP, Aiken T, Tatarskiy VV, Roninson IB, Broude EV. PMID: 33445730; PMCID: PMC7828184.
    View in: PubMed Mentions: 18 Fields:
    Translation:HumansCells
  8. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. Gynecol Oncol. 2021 02; 160(2):539-546. Fejzo MS, Chen HW, Anderson L, McDermott MS, Karlan B, Konecny GE, Slamon DJ. PMID: 33229045.
    View in: PubMed Mentions: 16 Fields:
    Translation:HumansCells
  9. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res. 2020 08 14; 22(1):89. O'Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, Gaither A, Hurvitz SA, Linnartz R, Rose K, Hirawat S, Slamon DJ. PMID: 32795346; PMCID: PMC7427086.
    View in: PubMed Mentions: 83 Fields:
    Translation:HumansAnimalsCells
  10. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition. Cells. 2020 03 06; 9(3). McDermott MSJ, Sharko AC, Munie J, Kassler S, Melendez T, Lim CU, Broude EV. PMID: 32155786; PMCID: PMC7140476.
    View in: PubMed Mentions: 23 Fields:
    Translation:HumansCells
  11. HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells. Cancers (Basel). 2019 Feb 08; 11(2). McDermott MSJ, Conlon N, Browne BC, Szabo A, Synnott NC, O'Brien NA, Duffy MJ, Crown J, O'Donovan N. PMID: 30743996; PMCID: PMC6406301.
    View in: PubMed Mentions: 22
  12. Concise total syntheses of (-)-jorunnamycin A and (-)-jorumycin enabled by asymmetric catalysis. Science. 2019 01 18; 363(6424):270-275. Welin ER, Ngamnithiporn A, Klatte M, Lapointe G, Pototschnig GM, McDermott MSJ, Conklin D, Gilmore CD, Tadross PM, Haley CK, Negoro K, Glibstrup E, Grünanger CU, Allan KM, Virgil SC, Slamon DJ, Stoltz BM. PMID: 30573544; PMCID: PMC7017906.
    View in: PubMed Mentions: 29 Fields:
    Translation:HumansCells
  13. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer. 2018 Oct 11; 18(1):965. Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J. PMID: 30305055; PMCID: PMC6180577.
    View in: PubMed Mentions: 12 Fields:
    Translation:HumansCells
  14. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells. Int J Oncol. 2017 Jun; 50(6):2221-2228. McDermott MSJ, Canonici A, Ivers L, Browne BC, Madden SF, O'Brien NA, Crown J, O'Donovan N. PMID: 28498399.
    View in: PubMed Mentions: 14 Fields:
    Translation:HumansCells
  15. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget. 2017 Feb 21; 8(8):12558-12575. McDermott MS, Chumanevich AA, Lim CU, Liang J, Chen M, Altilia S, Oliver D, Rae JM, Shtutman M, Kiaris H, Gyorffy B, Roninson IB, Broude EV. PMID: 28147342; PMCID: PMC5355036.
    View in: PubMed Mentions: 65 Fields:
    Translation:HumansAnimalsCells
  16. Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors. Cancer Res. 2014 Jul 15; 74(14):3821-33. Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S, McDermott MS, Browne BC, O'Donovan N, Crown J, Gogarty M, Byrne AT, O'Driscoll L. PMID: 24876102.
    View in: PubMed Mentions: 26 Fields:
    Translation:HumansAnimalsCells
  17. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat. 2012 Dec; 136(3):717-27. Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N. PMID: 23117852.
    View in: PubMed Mentions: 21 Fields:
    Translation:HumansCells

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs